about
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesA cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice.Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases.Long-term regulation of serotonergic activity in the rat brain via activation of protein kinase A.Enhancer and promoter chimeras in plasmids designed for intramuscular injection: a comparative in vivo and in vitro study.Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy.Sodium phosphate enhances plasmid DNA expression in vivo.Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes.Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth, and expression of transmitter-specific enzymes.Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain.Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro.Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188.Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations.Development and characterization of lyophilized DNA vaccine formulations.Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine.Spatial-temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA.II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines.Adjuvants for plasmid DNA vaccines.Effect of thyroid hormone analogs on the activity of choline acetyltransferase in cultures of dissociated septal cells.Gangliosides alter morphology and growth of astrocytes and increase the activity of choline acetyltransferase in cultures of dissociated septal cells.Cyclic AMP, but not basic FGF, increases the in vitro survival of mesencephalic dopaminergic neurons and protects them from MPP(+)-induced degeneration.Nerve growth factor increases choline acetyltransferase but not survival or fiber outgrowth of cultured fetal septal cholinergic neurons.A TaqMan reverse transcription polymerase chain reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products.I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra NeuronsIn VivoChronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesionsVaxfectin enhances the humoral immune response to plasmid DNA-encoded antigensVaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunizationPharmacological activities in thermal proteins: relationships in molecular evolution
P50
Q30352121-43A30A37-226E-4AEE-9C4D-D08B4A7FF8C6Q36385141-591001E0-2ECB-44E8-8E7B-D0AF255BFA56Q36694825-CB50F00A-07D1-4268-89C8-4381D8432901Q37813689-50DA3FD4-48FF-4093-B930-240583F0BC52Q38566410-09F620AA-A657-4D6A-9C22-AA45A94E963AQ38715616-3976AE64-A019-424F-84E3-5E74F4411D8FQ40872180-586DA05E-74E5-4AE8-AAC3-7A20260E4C2AQ40988260-E3BAE14C-81EF-4B56-9F89-273A43669BA8Q41208727-E03E8A8F-4037-44C1-92B2-AB47A7E1F3D6Q41751620-60375687-2433-4C70-BE77-7454EAD11FF4Q41900615-98005309-139F-4EAA-968B-04A105663EE9Q42502191-C00F09DE-9F9E-4DF9-9884-4AB318E2538BQ42508891-443DA892-17E2-4A77-BE04-30E1020BDDE2Q42514878-F7A090A4-701B-4EF7-BF73-8D3B5439FC94Q43799580-47D71BE0-83B9-4112-93DF-0A7F95B50676Q43949557-2AD24E50-4F17-443E-A5ED-0025FFEE39E7Q44585559-BE960503-C715-463A-8E02-F983D26C6C20Q45868023-8DBB725F-D5BA-40C0-9C57-3232DB97570FQ45878402-E8AA3984-622B-4A2A-A2A9-F1885D20323AQ45883348-E886BE69-9128-4552-9262-3B04F592DD0DQ46747186-26875E7E-5B78-48DA-8540-AF6AA3CB887BQ46986963-5F2878A5-16E4-4E8E-81D1-791BB2510967Q47768253-3E16A043-777E-4CCC-AE91-390D05F59D02Q48333362-94E4DF54-7C24-4B00-8EF5-00257E9E8821Q48464244-4689CCB7-6390-48BC-BDD5-1FA3354135B1Q48477028-F1B43DA7-3B3F-4E79-B1B4-BDDD6D4EC8C2Q48555966-AF09A267-7340-4DFC-88A8-6E0613E7B10FQ54540559-19922873-15E0-4302-98A8-0C2738A694A0Q54636822-0A3BF608-76F5-478C-A8BE-63314F5BE168Q61995916-2928B67F-CBB6-4D9A-B3E0-48FC71DA291EQ61995917-1030F0DE-7EF9-4C34-A4C0-B6A2C8A1B1DCQ71270737-C9225E0B-050A-4949-98F1-5D1B7D265645Q73563119-A3EA6179-EA12-459D-A15B-2F8C3B16E2A8Q73980732-0C4D93CB-18D9-4005-BA3C-C33C4CDA8A3FQ74476252-F63F9319-B941-47E0-A776-D4B0E12BBA0F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jukka Hartikka
@ast
Jukka Hartikka
@en
Jukka Hartikka
@es
Jukka Hartikka
@nl
Jukka Hartikka
@sl
type
label
Jukka Hartikka
@ast
Jukka Hartikka
@en
Jukka Hartikka
@es
Jukka Hartikka
@nl
Jukka Hartikka
@sl
prefLabel
Jukka Hartikka
@ast
Jukka Hartikka
@en
Jukka Hartikka
@es
Jukka Hartikka
@nl
Jukka Hartikka
@sl
P1053
J-9006-2014
P106
P1153
36718819100
P21
P31
P3829
P496
0000-0002-5143-2036